Meanwhile, Huang et al. [55] developed an in situ dendritic cell vaccine (HELA Exos) using TNBC organoids, which promoted the activation of dendritic cells and tumor-responsive CD8+ T cells, yielding significant anti-tumor activity. Here, CD8A is linked to neoplasm.